Incyte has reached a settlement with the Centers for Medicare & Medicaid Services (CMS) regarding rebate criteria for its eczema and vitiligo treatment Opzelura, according to a
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
The Federal Trade Commission may be winding down its ongoing insulin case against the three largest pharmacy benefit managers, as…
The top pharmacy benefit manager (PBM) in the U.S., CVS Caremark, will
Seeking a share of the first-line diffuse large B-cell lymphoma (DLBCL) market, Incyte believes Monjuvi’s positive phase 3…
In the wake of a recent safety scare in a confirmatory trial of its antibody-drug conjugate Zynlonta, ADC Therapeutics is…
Pfizer’s complaint about Alnylam’s activities at a cardiology congress has led the PMCPA to chastise the | Pfizer’s complaint…
The FDA has hit QOL Medical with an untitled letter over emails about Sucraid, accusing the company of creating a misleading…
